BioSpace News Archive

Daré Bioscience, Inc. today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two upcoming conferences.

Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that senior management will participate in the UBS Biotechnology Private Company Virtual Symposium, being held September 21-22, 2022.

RIGImmune Inc. today announced the acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2.

Jasper Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant.

Lipocine Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has agreed with Lipocine’s proposal for establishing the efficacy of LPCN 1154 through a single pivotal pharmacokinetic (“PK”) bridge to an approved IV infusion brexanolone via a 505(b)(2) NDA filing.

Moximed will present key data from the pivotal study of the MISHA™ Knee System at the 12th Orthopaedic Summit (OSET). A presentation of the implantable shock absorber’s (ISA’s) design and clinical evolution will also be presented by Andreas H. Gomoll, MD, Professor of Orthopedic Surgery at the Hospital for Special Surgery in New York.

Surgalign Holdings, Inc. today announced further advancement in the commercialization of its HOLO Portal™ surgical guidance system.

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that following an internal strategic review, the Management Team and Board have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing the advancement of its lead clinical program, LB1148.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), announced today that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing side effects and improving outcomes for cancer patients treated with radiation therapy (RT).

Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular’s Claudin 18.2 (CLDN18.2) MAbs.